Cephalon RFID Pilot: Drug Tracking ...

Cephalon RFID Pilot: Drug Tracking: Cephalon Selects OAT Foundation Suite for Item-Level Drug Tracking Pilot: OAT Foundation Suite Powers RFID Initiative to Drive Supply Chain Efficiencies and Ensure Patient Safety ...

Cephalon pilots RFID drug tracking as products move through the value chain to market. Broader RFID drug tracking implementation is expected, upon conclusion of the pilot period ...

... "OATSystems®, Inc., the recognized RFID framework leader, announced that Cephalon, Inc, an international biopharmaceutical company, has selected OAT Foundation Suite as the RFID software platform for use in a pilot program for tracking branded pharmaceuticals across the supply chain. For the pilot, OAT Foundation Suite will deliver end-to-end visibility of Cephalon’s products as they move across owned and outsourced facilities as well as selected drug wholesaler trading partners. Once the pilot project has proven successful, Cephalon will implement RFID utilizing the OAT Foundation Suite. " ...

OATSystems, Inc. is the recognized RFID framework leader with software that empowers businesses to achieve competitive advantage from radio-frequency identification (RFID). As pioneers in the development of RFID technology, OAT has been setting the standard in RFID for over half a decade and is responsible for industry firsts that include the largest scale and largest scope of deployments, as well as the most innovative approaches to providing enterprise-wide RFID solutions.

Additional resources on RFID pilots for drug tracking:

Purdue Pharma announced that it is placing RFID tags on bottles of the pain reliever OxyContin (oxycodone) to make it easier to authenticate, as well as to track and trace the medication. OxyContin, which is a controlled substance, has been subject to abuse, theft, and diversion. Based on the availability of sufficient RFID tags, Purdue also plans to tag bottles of Palladone (hydromorphone), a newly approved product to treat persistent moderate-to-severe pain.

Nine months after an FDA task force promoted the use of radio frequency identification (RFID) on drug packaging and labeling to prevent fake products from entering the supply chain, agency officials on November 15 announced that at least four pharmaceutical makers are participating in pilot projects or studies to test the effectiveness of RFID in combating counterfeiting.

GlaxoSmithKline [NYSE: GSK) announced that it will begin using radio frequency identification (RFID) tags in the next 12 to 18 months on at least one product deemed susceptible to counterfeiting in order to more effectively monitor its progress from the company to the patient. GSK is partnering in this pilot project with the US Food and Drug Administration, which is encouraging the use of RFID technology to protect American patients from the growing risk of counterfeit and diverted medicines.